- Home
- LCNB vs DRUG Comparison
LCNB vs DRUG Comparison
Compare LCNB & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCNB
- DRUG
- Stock Information
- Founded
- LCNB 1877
- DRUG 2019
- Country
- LCNB United States
- DRUG United States
- Employees
- LCNB N/A
- DRUG N/A
- Industry
- LCNB Major Banks
- DRUG Pharmaceuticals and Biotechnology
- Sector
- LCNB Finance
- DRUG Health Care
- Exchange
- LCNB Nasdaq
- DRUG Nasdaq
- Market Cap
- LCNB 212.3M
- DRUG 210.7M
- IPO Year
- LCNB N/A
- DRUG N/A
- Fundamental
- Price
- LCNB $16.94
- DRUG $39.06
- Analyst Decision
- LCNB
- DRUG
- Analyst Count
- LCNB 0
- DRUG 0
- Target Price
- LCNB N/A
- DRUG N/A
- AVG Volume (30 Days)
- LCNB 20.6K
- DRUG 8.3M
- Earning Date
- LCNB 10-21-2024
- DRUG 11-18-2024
- Dividend Yield
- LCNB 5.12%
- DRUG N/A
- EPS Growth
- LCNB N/A
- DRUG N/A
- EPS
- LCNB 0.52
- DRUG N/A
- Revenue
- LCNB $74,686,000.00
- DRUG N/A
- Revenue This Year
- LCNB N/A
- DRUG N/A
- Revenue Next Year
- LCNB $6.49
- DRUG N/A
- P/E Ratio
- LCNB $33.05
- DRUG N/A
- Revenue Growth
- LCNB 3.03
- DRUG N/A
- 52 Week Low
- LCNB $12.42
- DRUG $0.93
- 52 Week High
- LCNB $17.27
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- LCNB 70.64
- DRUG 57.89
- Support Level
- LCNB $15.95
- DRUG $41.64
- Resistance Level
- LCNB $17.27
- DRUG $50.25
- Average True Range (ATR)
- LCNB 0.35
- DRUG 6.11
- MACD
- LCNB 0.18
- DRUG -1.96
- Stochastic Oscillator
- LCNB 97.05
- DRUG 13.77
About LCNB LCNB Corporation
LCNB Corp operates within the financial sector in the United States. As the holding company of the National Bank, it conducts the business of providing commercial and personal banking services. Its suite of banking products includes commercial and industrial loans, consumer loans, safe deposit boxes, night depositories, cashier's checks, utility bill collections, and notary public service. Besides, it provides the avenue of United States Treasury notes, the United States agency notes, certificates of deposit, and equity securities.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.